print page

31.12.2018

EMBO Young Investigator Award for Hind Medyouf

Dr. Hind Medyouf, a DKTK faculty member at the Frankfurt site and a group leader at the Institute for Tumor Biology and Experimental Therapy and the Frankfurt Cancer Institute, has been awarded the prestigious European Molecular Biology Organization (EMBO) Young Investigator Programme (YIP) for the year 2019. She joins an active network of 102 current and 314 past Young Investigators.

Find more information on the EMBO Young Investigator Award here.


About Hind Medyouf

Dr. Medyouf joined the Institute for Tumor Biology and Experimental Therapy in October 2014, after postdoctoral training at the Terry Fox Laboratory in Canada and the German Cancer Research Center. Her current research is focused on exploring the role of the tumor microenvironment in leukemia and solid cancer metastasis. In particular, the group is investigating the complex cellular interactions and molecular mechanisms by which tumor cells co-opt their surrounding stroma to promote immune escape and therapeutic resistance.

The EMBO Young Investigator Programme will facilitate and further promote Dr. Medyouf’s collaborations with colleagues in the EMBO community, which will be crucial to achieve her research goals. “I am thrilled and honored to join such an outstanding programme. The EMBO YIP brings together some of the best young minds in science across Europe. It helps by providing mentorship, facilitating travel to meetings, collaborations and access to EMBL facilities. This is extremely attractive, as my lab members can also take advantage of many of these benefits. The program simply offers great opportunities for our group”, Dr. Medyouf said about the EMBO award.

Dr. Medyouf’s research program is currently supported by the European Research Council (ERC Starting grant), the German Research Foundation (DFG), the German José Carreras Leukemia Foundation (DJCS), the German Cancer Consortium (DKTK) as well as intramural funding from the Institute for Tumor Biology and Experimental Therapy and the Frankfurt Cancer Institute.